On June 6, 2018 Rubius Therapeutics, a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, reported the appointment of Pablo J. Cagnoni, M.D., as Chief Executive Officer (Press release, Rubius Therapeutics, JUN 6, 2018, View Source [SID1234527211]). Torben Straight Nissen, Rubius’ President, will partner with Dr. Cagnoni to continue to advance the company’s pipeline and other business objectives.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Pablo’s deep industry expertise and role in the development and commercialization of more than 20 life-changing treatments positions him to lead Rubius as we continue to advance a new class of medicines to treat cancer, autoimmune diseases and rare diseases," said David Epstein, Chairman of Rubius Therapeutics. "We are extremely pleased to welcome Pablo as CEO."

Over the course of Dr. Cagnoni’s career as an oncologist and pharmaceutical executive, he has played a key role in the development, approval and commercialization of several transformative medicines, including Afinitor, Kyprolis and Tarceva. He most recently served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing novel treatments for cancer. Prior to Tizona, Dr. Cagnoni served as President of Onyx Pharmaceuticals, Global Head of Clinical Development at Novartis Oncology, and Chief Medical Officer at Allos Therapeutics and OSI Pharmaceuticals, respectively. Dr. Cagnoni received his M.D. from the University of Buenos Aires School of Medicine, and completed fellowships in Hematology and Oncology at the Mount Sinai Medical Center, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

"I am honored to join Rubius as CEO to continue building the company’s broad and diverse pipeline of Red Cell Therapeutics in multiple therapeutic areas, while making a significant impact for patients with serious diseases," said Dr. Cagnoni. "I look forward to partnering with Torben and the entire team

On June 6, 2018 Peloton Therapeutics, Inc., reported dosing of the first patient in a Phase 2 trial evaluating the efficacy and safety of lead investigational oncology agent , PT2977, to treat von Hippel-Lindau (VHL) disease-associated kidney cancer (Press release, Peloton Therapeutics, JUN 6, 2018, View Source [SID1234527212]). PT2977 is a once-daily, oral inhibitor of HIF-2α, a transcription factor that has been implicated in the development and progression of renal cell carcinoma (RCC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The initiation of this Phase 2 trial is an important milestone for Peloton and a critical step towards helping patients with this rare condition which can have serious lifelong health consequences," said Mohammad Hirmand, M.D., Peloton’s Chief Medical Officer. "The safety, pharmacokinetics, and clinical activity that we have observed in a Phase 1 trial of PT2977 provides insights into its potential to improve outcomes for patients with kidney cancer. We look forward to continuing clinical evaluation of this novel oral HIF-2α inhibitor."

The primary objective of the Phase 2 trial is to evaluate the efficacy of PT2977 for the treatment of VHL disease-associated renal tumors as measured by overall response rate. Secondary objectives include duration of response, time to response, progression free survival, and time to surgery for VHL disease-associated renal tumors. The trial will also evaluate the efficacy of PT2977 in other VHL disease-associated tumor types as well as the safety and pharmacokinetics of PT2977. Patients will be evaluated radiologically approximately every 12 weeks while continuing in the study.

"Unfortunately, there are no approved systemic therapies available for VHL disease. Currently, the only option is surgery, sometimes required multiple times which can be devastating for patients and does not cure the disease," said Eric Jonasch, M.D., Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine; Director, VHL Clinical Center, The University of Texas MD Anderson Cancer Center. "We are excited about the opportunity to study PT2977 which may offer a new option as an orally available agent that could reduce the need and frequency of surgical intervention for patients with VHL-associated kidney disease."

Peloton’s drug discovery and development efforts focus on identifying novel compounds capable of modulating complex protein-protein interactions that drive disease which have eluded conventional small molecule approaches. Peloton has the only clinical stage small-molecule inhibitors of HIF-2α, and PT2977 has demonstrated a favorable profile in a Phase 1 study in patients with advanced solid tumors including RCC.

The study will enroll 50 patients at clinical trial centers across the United States and Europe. More information about the trial is available at www.clinicaltrials.gov, identifier NCT NCT03401788.

About VHL Disease

Von Hippel-Lindau (VHL) disease is a rare, hereditary cancer syndrome in which affected individuals have a mutation and/or deletion of the tumor suppressor VHL gene, and are at risk for the development of multiple tumors including renal cell cancer. The global incidence of VHL is estimated to be one in 36,000 people.

About PT2977

Peloton has succeeded in creating a series of orally-available small molecules that bind to HIF-2α and inhibit its transcription of disease-promoting genes. PT2977 is a once-daily, orally-active agent that blocks hypoxia-inducible factor-2α (HIF-2α). It is a structurally-related compound designed to be more potent with less pharmacokinetics variability compared to PT2385. PT2977 has demonstrated anti-tumor activity with a favorable safety profile in an early-stage clinical study in patients with solid tumors. Given its superior profile, PT2977 is the lead agent being developed in oncology by Peloton. In addition to the international Phase 2 trial of PT2977 in VHL disease-associated RCC, Peloton is evaluating the agent in a Phase 1 clinical trial for the treatment of advanced RCC.

On June 6, 2018 BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, reported that the company will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA (Press release, BeiGene, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353457 [SID1234527195]). The presentation is scheduled for 11:20 AM PST on Tuesday, June 12, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source An archived replay will be available for 90 days following the event.

On June 6, 2018 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) reported that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host one-on-one meetings (Press release, CTI BioPharma, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353463 [SID1234527196]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

On June 6, 2018 Seattle Genetics, Inc. (NASDAQ:SGEN) reported that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 1:20 p.m. Pacific Time (Press release, Seattle Genetics, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353475 [SID1234527197]). The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!